Maggie L. Shaw

Cranbury

Senior Editor at MJH Life Sciences

Editor

Featured in: Favicon

mjhlifesciences.com Favicon

newsbreak.com Favicon

ajmc.com

contemporaryobgyn.net Favicon

dermatologytimes.com Favicon

contemporarypediatrics.com Favicon

managedhealthcareexecutive.com Favicon

drugtopics.com Favicon

ophthalmologytimes.com Favicon

centerforbiosimilars.com + 3 more

Articles

Suboptimal Care for PAH Persists Among Women

1 week ago | ajmc.com | Maggie L. Shaw

Improvements in disease awareness, communication between patients and their health care providers, and treatments for pulmonary arterial hypertension (PAH) are needed among women living with this subtype of pulmonary hypertension, according to research findings gathered via survey presented at the recent American Thoracic Society 2025 International Conference.1 The investigation encompassed childbearing women and women of childrearing age, 2 populations of patients who face higher rates of...
We Do Our Best to Serve the Community: Cathy Eng, MD, FACP, FASCO

1 week ago | ajmc.com | Maggie L. Shaw |Cathy Eng

Concluding this recent interview with Cathy Eng, MD, FACP, FASCO, she speaks on several of the clinical and operational priorities that academic medical centers make front-and-center when caring for underserved populations receiving treatment for cancer. She also stresses recognizing barriers to care access and remaining flexible with patient outreach.
Accurate Diagnosis of Myasthenia Gravis in Pediatric Patients Is Challenging: Jonathan Strober, MD

1 week ago | ajmc.com | Maggie L. Shaw |Jonathan Strober

Jonathan Strober, MD, is a pediatric neurologist, director of clinical services for child neurology and of the Muscular Dystrophy Clinic at UCSF Benioff Children's Hospital, and an investigator on the phase 2/3 Vibrance-MG study (NCT05265273), which is evaluating nipocalimab for use in pediatric patients in the US, Japan, Netherlands, and Poland.
Living With HIV, Leading Through Experience: Bridgette J. Picou, LVN, ACLPN

2 weeks ago | ajmc.com | Maggie L. Shaw |Bridgette Picou

In the bio for Bridgette J. Picou, LVN, ACLPN, stakeholder liaison, The Well Project, Brooklyn, New York, it states, “Sitting at the intersections of being Black, a woman, and living with HIV, her goal is to remind people that there are lives being lived behind a three-or four-letter acronym.” For the third and final part of this discussion, she addresses her impact as a Black woman living with HIV and as a community worker, as well as advocating for all women living with HIV.
5 Rare Disorders Named for Pioneering Female Scientists

2 weeks ago | ajmc.com | Maggie L. Shaw

Each year, May is recognized as National Women’s Health Month—or alternatively, Women’s Health Awareness Month—with the week beginning on Mother’s Day observed as National Women’s Health Week.
Barriers to Timely Diagnosis of Generalized Myasthenia Gravis: Marla Black Morgan, MD

2 weeks ago | ajmc.com | Maggie L. Shaw |Marla Black Morgan

In a recent interview with The American Journal of Managed Care®, Marla Black Morgan, MD, neurologist with Phoebe Neurology Associates, discussed the findings from her investigation into the diagnostic journeys of patients with rare neuromuscular conditions. She presented findings from her Project ASPIRE (eliminAte diSparities and Promote equIty in Rare diseasE) at the recent American Academy of Neurology annual meeting.
MRD Status Guides Consolidation With Cema-Cel in ALPHA3 Trial: Fred Locke, MD

2 weeks ago | businessandamerica.com | Maggie L. Shaw

The phase 1 ALPHA (NCT03939026) and phase 1/2 ALPHA2 (NCT04416984) trials are investigating cemacabtagene ansegedleucel (cema-cel), an allogeneic chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory large B-cell lymphoma. Findings from these 2 trials comprise the foundation for the phase 2 ALPHA3 (NCT06500273) trial, which is evaluating first-line consolidation treatment with cema-cel in patients with a low disease burden.
MRD Status Guides Consolidation With Cema-Cel in ALPHA3 Trial: Fred Locke, MD

2 weeks ago | ajmc.com | Maggie L. Shaw |Frederick Locke

The phase 1 ALPHA (NCT03939026) and phase 1/2 ALPHA2 (NCT04416984) trials are investigating cemacabtagene ansegedleucel (cema-cel), an allogeneic chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory large B-cell lymphoma. Findings from these 2 trials comprise the foundation for the phase 2 ALPHA3 (NCT06500273) trial, which is evaluating first-line consolidation treatment with cema-cel in patients with a low disease burden.
Specialty Drug Users to Gain Relief Under Medicare Reforms

3 weeks ago | ajmc.com | Maggie L. Shaw

An analysis comparing estimated out-of-pocket (OOP) costs in 2023 and 2026 for patients with Medicare Part D prescription drug coverage—before and after 3 cost-reducing provisions took effect—found that the Medicare Prescription Payment Plan (MPPP) may help patients maximize their savings and benefit from these changes.1 A study published online today in JAMA Health Forum examined the potential impact of 3 provisions under the Inflation Reduction Act (IRA) meant to reduce Medicare Part D OOP...
Rozanolixizumab for gMG Approved in Japan for Self-Administration

3 weeks ago | ajmc.com | Maggie L. Shaw

On May 9, Japan’s Pharmaceuticals and Medical Devices Agency followed the European Union’s lead in approving rozanolixizumab (Rystiggo; UCB) for generalized myasthenia gravis via self-administration.1,2 Patients in the country now have the option to use a manual push or syringe pump method to administer at home the humanized anti–neonatal Fc receptor monoclonal antibody that targets immunoglobulin G.